180 Life Sciences Corp.
NasdaqCM ATNF
180 Life Sciences Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -4.86 M
-
180 Life Sciences Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -43.58 M, a -52.67% change year over year.
-
180 Life Sciences Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -28.54 M, a 37.98% change year over year.
-
180 Life Sciences Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -46.02 M, a -98.52% change year over year.
-
180 Life Sciences Corp. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -23.18 M, a -578.31% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
| CEO | Sir Marc Feldmann Ph.D. |
| IPO Date | June 27, 2017 |
| Location | United States |
| Headquarters | Building 4 |
| Employees | 4 |
| Sector | Health Care |
| Industries | |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Past 5 years
USD 1.75
USD 3.58
USD 1.95
USD 1.52
USD 0.57
USD 1.49
USD 2.00
StockViz Staff
January 15, 2025
Any question? Send us an email